A Glimpse Into The Expert Outlook On AnaptysBio Through 6 Analysts
Portfolio Pulse from Benzinga Insights
AnaptysBio (NASDAQ:ANAB) has received mixed ratings from 6 analysts, with a majority being bullish. The average 12-month price target has increased to $57.83. Analysts have adjusted their ratings and price targets, reflecting their views on AnaptysBio's market position and financial performance.
October 21, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AnaptysBio has received a mix of bullish and somewhat bullish ratings from analysts, with an average price target increase to $57.83. Analysts have adjusted their ratings and price targets, indicating a positive outlook on the company's market position.
The majority of analysts have a bullish outlook on AnaptysBio, with an increase in the average price target. This suggests a positive short-term impact on the stock price as analysts' ratings can influence investor sentiment and trading activity.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100